Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor – Pipeline Review, H2 2016, provides an overview of the Peripheral Nerve Sheath Tumor (Oncology) pipeline landscape.
Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Nerve Sheath Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Peripheral Nerve Sheath Tumor.
Peripheral Nerve Sheath Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Oncology).
- The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Bexion Pharmaceuticals LLC
EpiZyme Inc
Merck & Co Inc
Novartis AG
Pfizer Inc
Plexxikon Inc
Vyriad Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Overview 6
Therapeutics Development 7
Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview 7
Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Comparative Analysis 8
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Development by Companies 9
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Investigation by Universities/Institutes 10
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Development by Companies 13
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Investigation by Universities/Institutes 14
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development 15
Bexion Pharmaceuticals LLC 15
EpiZyme Inc 16
Merck & Co Inc 17
Novartis AG 18
Pfizer Inc 19
Plexxikon Inc 20
Vyriad Inc 21
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
axitinib - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
BXQ-350 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
everolimus - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ganetespib - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Oncolytic Virus to Target CD46 for Oncology - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
pembrolizumab - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
pexidartinib - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
tazemetostat - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects 109
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones 110
Featured News & Press Releases 110
Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer 110
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112
List of Tables
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2016 7
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 15
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by EpiZyme Inc, H2 2016 16
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, H2 2016 17
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, H2 2016 18
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, H2 2016 19
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, H2 2016 20
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, H2 2016 109
List of Figures
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2016 7
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Top 10 Targets, H2 2016 23
Number of Products by Stage and Top 10 Targets, H2 2016 23
Number of Products by Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29
